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Abstract 
This papes discusses the theory and application of statistical methods for describing and 
analyzing survival times of the renal dialysis patients : a) from the first diagnosis until the 
time of death, and b) on each mode of given treatment. The paper also tries to predict the 
variables significantly effecting the survival time of renal dialysis patients. The paper 
makes use of and focuses on the data sets containing patient hospital records, patients’ 
identity and hospital code centre. To meet the desired aims, the paper uses two prominent 
methods of survival analysis including the Kaplan-Meier and Cox Proportional Hazard 
model. The result shows that survival time on the first treatment depends on mode of 
treatment and it quite low approximately 18 days for median time on hospital outpatient 
CAPD. Similarly, survival time on the second treatment is quite low about 24 days for the 
median time on hospital outpatient CAPD. It was also indicated that the survival time of 
renal dialysis patient depends on the number of treatments, the number of treatment 
changes, place of treatment, age and the first treatment. 
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1.  Background 
Chronic or unspecified renal failure was listed as a cause of death of 9160 
Australians (7.1% of all deaths) (Australian Bureau of Statistics, special data request, 2002). 
Each year, more than 1700 people with end-stage renal disease (ESRD) start dialysis or 
receive a transplant (Rush, ANZDATA Registry Report 2001). Most would have had chronic 
renal impairment (CRI) for years. These figures suggest that the impact of CRI is substantial 
and that in order to prevent progression to ESRD, it is important to develop systems for its 
detection and management by providing relevant disease related information. Furthermore, it 
was reported that each year, there are about 2000 Australian adults who commence dialysis, 
half of whom are aged over 60 years. 
Renal Dialysis is an “artificial method of maintaining the chemical balance of the 
blood when the kidneys failure happens.” This method has increasingly developed in some 
countries. In NSW, Australia, the development of this renal dialysis is approximately 6% and 
this has exceeded the population growth of only 1% (Gibberd et al., 2004).  
 In this paper, it will be applied a number of statistical methods to analyse renal 
dialysis data supplied by ANZDATA and NSW registry database in 1995 and has aims as 
follows: 
- To describe and analyse the survival time of the renal dialysis patients: a) from 
the first diagnosis until the time of death, b) on each mode of given treatment 
and c) if they change the modes of given treatment. 
- To predict the survival time for each treatment mode based on age, sex, region, 
time since diagnosis and the number of treatment changes. 
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2. Overview of Used Methods 
 
2.1. Survival Analysis 
 
Historically, the trigger of the emergence of the use of survival analysis goes back 
to the World War II. During this war, the interest of scrutinizing the reliability or failure time 
of military equipment has seemingly inspired the new application of statistical methods, 
which then are known well as survival analysis methods. In the development of survival 
analysis techniques, even though extensively assigned in many areas of social, economic and 
in engineering for looking at reliability and failure time analysis, it has been primarily 
developed in the biological and medical researches. This is due to survival analysis methods 
being well suited for the research in the latter two sciences. As far as, for example clinical 
trials in medical research are concerned, the studies of intervention follow up could start 
without all experimental units enrolled at the beginning of study time and could finish before 
all experimental units had went through an event. In other words, there will be subjects of the 
experiment who choose to either quit participating or move away that is difficult to follow or 
die from some unrelated event (Smith et al., 1990). 
To report survival times, some traditional methods of statistics such as the standard 
parametric and nonparametric statistics mainly describing the average survival could be used. 
The problem that could arise from applying those traditional methods is the censoring some 
objects of the study. Therefore, survival analysis needs to be based on censored observations. 
Censoring is what distinguishes survival analysis from other classical types of statistical 
analyses.  
In general, survival time could be defined as “the analysis of data representing the 
time to occurrence of a certain point or endpoint (time-to-event data)” (Galbriath, 2004). The 
term “endpoints” could indicate death, release of pain and reappearance of symptoms. In most 
of cases, the application of survival analysis is aiming at identifying predictive variables for 
survival time or comparing the survival times of a number of different objects in a study.   
To be applied, survival analysis requires at least three conditions including: 
1. A well-defined time origin and therefore it is not ambiguous e.g. time of entry to 
study, which often corresponds to different times fir different individuals. 
2. A scale for measuring the passage of time must be agreed, generally real time 
3. A well-defined endpoint that implies that the meaning of failure must be 
completely clear (Galbriath, 2004; Cox & Oakes, 1984). 
As mentioned before, censoring is very important in conducting survival analysis. 
Censoring takes place when an individual’s life length, for example, is known to occur only in 
a certain period of time (Klein & Moeschberger, 1997).    
There are three kinds of censoring. These include right censoring, left censoring and 
interval censoring. The terms of “right”, “left”, and “interval” censoring indicates the range in 
which survival time is known to locate.  In relation to the censoring issues, this study mainly 
deals with right censoring.  
In Galbraith’s observation, right censoring is the common type of censoring in 
survival analysis and occurs when we only know that the survival time exceeds a certain 
value. To make it clear, she takes a five-year study of mortality from cancer as an example. 
According to her, survival times will be right censored for patients who: 
 are alive at the end of the five year period 
 drop out or become lost to follow-up during the study; or 
 die from some other cause during the study (Galbriath, 2004; Klein & 
Moeschberger, 1997). 
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2.2. Kaplan Meier Survival Analysis 
 
In dealing with censored data, the Kaplan Meier procedure is an important tool. It is 
a method for time to event models based on the estimation of conditional likelihood at each 
time point when a particular event takes place. The product limit of the probabilities estimates 
the survival rate at each point in time. By using this method, we can make comparisons of the 
entire survival (or failure) rates between two or more groups in order to see the effect of a 
particular mode of treatments on the survival time of the patients. The groups here could be 
age, sex, region etc.  
The fundamental idea of Kaplan Meier model is to order the observation of the 
failure time variable and to let the right endpoint of Ii, τi, be the i
th
 ordered observation. For 
this reason τ1, τ2, …………….., τk indicate distinct event times (Miller Jr., 1981). This can be 
illustrated as follows  
 
  I1 I2 I3 I4  Ik-1  Ik 
                 (      ]  (          ]  (  ]      (     ]                (           ]       (         ] 
 
                 0          1            2         3         4                 k-2            k-1               k 
                                           = failure                    = censored 
Figure 1. Ordering the Observations of The Failure Time Variable. 
 
There are two kinds of observation that can be conducted including no tied 
observations and tied observations. The first observation considers that all the event times are 
different while the latter assume that uncensored observations take place just before the 
censored observations. Meanwhile the Kaplan Meier estimate of survival with no ties is  
   


tX
i
i
ptS ˆˆ =
 i
i tX i
n










1
1 =
 i
i tX
in











1
1
1 =
 i
i tX
in
in











1
 
In calculating the Kaplan Meier survival estimates for one or more groups, we need 
a survival platform that can be used as a basis of getting information for more compound 
model.  This Kaplan Meier Survival platform will indicate a plot illustrating the predicted 
survival function for each group and even for the whole sample. It also computes and lists 
survival function for each group and for the combined sample.        
In this paper, the Kaplan Meier analysis is used to estimate three survival times of 
renal dialysis patients who have different treatment regimes. The first one is survival time on 
the first treatment, the second one is survival time on the second treatment and the last one 
survival time from the first diagnosis until either the time of death or the end of study. 
Illustratively this can be drawn as follows 
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Period of Study : 
T1,2,3 :  Time on a given treatment 
S1 :  Time to death (uncensored) 
S2 :  Time to death (censored) 
Figure 2.  The Three Survival Times of Renal Dialysis Patients. 
Given the picture above, time on the first treatment is (T2  - T1) and time on the 
second treatment  is (T3 – T2). Meanwhile time from the third mode of given treatment until 
the end of the study is considered as censored data. 
After producing the Kaplan Meier estimate of the survival curve for renal dialysis 
patients, the median survival time was estimated. The median survival time is defined to be 
the smallest observed survival time for which the estimated survival function is less than 0.5 
(Glantz, 2001). 
 
 
2.3. Cox Proportional Hazard Model (Cphm) 
The proportional hazard model (phm) is similar to common regression. The 
different feature of the phm compared with other regression models is that it can be used 
when we are dealing with data containing censored cases (Stephen, 2000).  
In its simplest form, the phm can be the following equation: 
hi (t) = e
x
i  
β 
ho (t) 
hi (t) is the hazard at time t of the i
th 
individual and ho (t) is the baseline hazard at time t. Xi  is a 
vector of covariate values corresponding to the i
th 
individual and β is a vector of coefficients 
to be estimated. Therefore, it is clear that ho (t) is dependent only on time and e
x
i  
β 
 depends 
only on the covariates and regression coefficients.    
Given the simplest equation of the phm above, it can be furthermore noticed that if 
Xi  = 0 then the hazard function of the i
th 
individual is the baseline hazard function. 
Additionally, if both sides of the equation are divided by ho (t) , it can be seen that every value 
of the i
th individual’s hazard function is s constant proportion of the baseline hazard. This is 
the reason why the term proportional is used.     
Cox then proposed a semi-parametric method by which the regression parameters β 
can be estimated while leaving the baseline hazard function arbitrary (CCEB, 2004). 
 
 
T1                          T2                                  T3                                  Died                 September 2002 
S1 
T1                                                     T2                 
S2 
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3. Results of Analysis of Renal Dialysis Data 
 
3.1. Application for Kaplan Meier Model 
In this section, the survival time of the renal dialysis patients: a) from the first 
diagnosis until the time of death, b) on each mode of given treatment are examined. In doing 
so, curves of survival are generated by using JMP 5.1. 
 
 
 
Figure 3. Survival Curve for The First Treatment By Treatment Mode. 
 
Kaplan-Meier estimates are obtained for the first treatment. From the graph, it appears that 
survival is the best for transplant Aust/NZ than for others. After 152 days just over 1.52% of 
the transplant patients have changed treatment. However, hospital outpatient CAPD appears 
to have the shorter time before changing treatment. After 2 days, over 1.87% of these 
patients’ have changed treatment. The p-value for the logrank test is 0.0000 with df = 4 and 
for the Wilcoxon test is <0.0001 with df = 4. We could conclude that there are statistically 
significant differences in time on the first treatment for all different types of the first 
treatment. 
 Overall, the number of patients who died from 1996 to September 2002 was 1257 
and the number of patients who were still alive at the end of the data was 2729. All patients in 
the second modes of treatment, after an initial drop of approximately 0.35% in survival within 
the first days after first treatment, survival steadily decreases but not linearly, over the 2359-
day period. The median survival time is 1334 days. Since the final time recorded is not a 
censored observation, the report does not indicate biased mean estimate. The mean estimate is 
not a lower bound for the true mean (1280 days). 
 
 
Hosp outpatient CAPD 
Hospital APD/IPD 
Hospital HD 
Satellite HD 
Transplant Aust/NZ 
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Figure 4. Survival Curve for The Second Treatment. 
 
The smallest number of cases for the second treatment is hospital HD, whereas the large 
numbers of cases are home CAPD and satellite HD. However, the home CAPD has the larger 
variation than satellite HD. 
 
 
Figure 5. Survival Curve for The Second Treatment By Treatment Mode. 
 
Kaplan-Meier estimates are obtained for the second treatment. From the graph, it appears that 
time on the second treatment is less for hospital outpatient CAPD than for others. After 3 days 
just over 6.27% of the hospital outpatient have changed treatment. The p-value for the 
logrank test and for the Wilcoxon test is <0.0001 with df = 8. We could therefore conclude 
that there are statistically significant differences in the first treatment for all different types of 
the second treatment.  
 The p-value for the logrank test is <0.0001 with df = 6, and for the Wilcoxon test is 
0.05 with df = 6. We could therefore conclude that there are differences in time on the second 
treatment. 
Tests Between Groups 
Test ChiSquare DF Prob>ChiSq 
Log-Rank 3.8329 6 0.6993 
Wilcoxon 11.6038 6 0.0714 
 
Home APD/IPD 
Home CAPD 
Home HD 
Hosp outpatient CAPD 
Hospital APD/IPD 
Hospital HD 
Own kidney function recover 
Satellite HD 
Transplant Aust/NZ 
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The p-value for the logrank test is 0.69 with df = 6, and for the Wilcoxon test is 0.07 with df = 
6. We could therefore conclude that there are no differences in time on the second treatment 
for home APD/IPD. 
The time on treatment until death is given for those patients who started to receive 
the first mode of renal dialysis treatment in or after 1996 until death. We censored the patients 
who were still alive at the end of the data (September 2002), and were uncensored if the 
patient died.  
 
 
 
Figure 6.  Survival Curve for All The First Diagnosis to Death 
The Kaplan-Meier estimates are obtained for all types of the first mode of treatment to death. 
From the graph, it appears that compared to other treatments, survival time is the best for the 
transplant Aust/NZ and the worse for the three hospital treatments (HD, CAPD and 
APD/IPD). After 1864 days just over 6.25% of the transplant Aust/NZ patients have died. 
Meanwhile, the numbers of patients who have died under the hospital HD was 844 and after 
2070 days just over 50.04% have died. The p-value for the logrank test and for the Wilcoxon 
test is <0.0001 with df = 4. We therefore conclude that there are statistically significant 
differences in survival time for the entire first mode of treatment till death. 
 
Survival By Place of Treatment  
-  Hospital 
 
 
Figure 7.  Survival Curve in Hospital for The First Modes of Treatment 
 
Overall, the number of patients who died from 1996 to September 2002 was 1237 and the 
number of patients who were still alive at the end of the data was 2591. All patients in the 
first modes of treatment, after an initial drop of approximately 3.75% in survival within the 
first days after first treatment, survival steadily decreases but not linearly, over the 2353-day 
Hosp outpatient CAPD 
Hospital APD/IPD 
Hospital HD 
Satellite HD 
Transplant Aust/NZ 
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period. The median survival time is 450 days. Since the final time recorded is a censored 
observation, the report indicates a biased mean estimate. The biased mean estimate is a lower 
bound for the true mean (894 days). 
 
 
Figure 8. Survival Curve in Hospital for The Second Modes of Treatment. 
Overall, the number of patients who died from 1996 to September 2002 was 413 and the 
number of patients who were still alive at the end of the data was 876. All patients in the 
second modes of treatment, after an initial drop of approximately 20.61% in survival within 
the first days after first treatment, survival steadily decreases but not linearly, over the 2023-
day period. The median survival time is 202 days. Since the final time recorded is a censored 
observation, the report indicates a biased mean estimate. The biased mean estimate is a lower 
bound for the true mean (810 days). 
 
-  Home 
No home-based on renal dialysis treatment was found at the modes of treatment. 
 
 
Figure 9.  Survival Curve in Home for The Second Modes of Treatment. 
 
Overall, the number of patients who died from 1996 to September 2002 was 472 and the 
number of patients who were still alive at the end of the data was 1104. All patients in the 
second modes of treatment, after an initial drop of approximately 0.25% in survival within the 
first days after first treatment, survival steadily decreases but not linearly, over the 2281-day 
period. The median survival time is 1505 days. Since the final time recorded is not a censored 
observation, the report does not indicate a biased mean estimate. The mean estimate is not a 
lower bound for the true mean (1400 days). 
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-  Satellite 
 
 
 
Figure 10. Survival Curve in Satellite for The First Modes of  Treatment. 
 
Overall, the number of patients who died from 1996 to September 2002 was 20 and the 
number of patients who were still alive at the end of the data was 138. All patients in the first 
modes of treatment, after an initial drop of approximately 0.25% in survival within the first 
days after first treatment, survival steadily decreases but not linearly, over the 2281-day 
period. Since the final time recorded is a censored observation, the report indicates a biased 
mean estimate. The biased mean estimate is a lower bound for the true mean (1283 days). 
 
 
Figure 11.  Survival Curve in Satellite for The Second Modes of Treatment. 
 
Overall, the number of patients who died from 1996 to September 2002 was 241 and the 
number of patients who were still alive at the end of the data was 527. All patients in the 
second modes of treatment, after an initial drop of approximately 0.13% in survival within the 
first days after first treatment, survival steadily decreases but not linearly, over the 2201-day 
period. The median survival time is 1220 days. Since the final time recorded is a censored 
observation, the report indicates a biased mean estimate. The biased mean estimate is a lower 
bound for the true mean (1225 days). 
 
3.2. Application for Cox Proportional Hazard Model (Cphm)  
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In this section, the identification of some variables that affecting survival time of 
renal dialysis patients is conducted by using STATA 8. Initially, a frequency check of all 
variables was undertaken. The variables of interest for these analyses are: sex, number of 
treatments used (treat_used), age1, and number of treatment changes (treat_change), post 
code (postcd), year and first treatment (treat1_cd). Backward stepwise regression was 
undertaken (see appendix d). The final model included 5 variables significant at the 5% level. 
Those variables embrace: age (category2: 5-14 years, category 3: 15-24 years, category 4: 25-
34 years, category 5: 35-44 years, category 6: 45-54 years and category 7: 55-64 years), 
number of change treatments, year (1997 to 2001) and the first treatments (satellite HD and 
transplant Aust/NZ). 
 
 
4. Conclusion 
Having analysing the survival time of renal dialysis patients who have different 
treatment regimes it is clearly can be seen that the hospital HD treatment is the command 
mode of the first treatment, which is increased every year. It was also found that in 1996, 25% 
of patients had changed treatment after 50 days of treatment but it was 307 days in 2001. 
Meanwhile, home CAPD is the comment mode of the second treatment used by renal 
dialysis’s patients. Overall survival time of renal dialysis patients depend on the number of 
treatments, the number of treatment changes, places of treatment, age and the first treatment. 
Specifically we can identify the most significant variables that affect the survival time of the 
renal dialysis patients. These variables consists of age group of 15-24 years old and 75-84 
years old, number of treatment used, number of treatment changes, satellite for the place of 
treatment and transplant AUST/NZ for the first treatment. 
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